Medtronic lands Euro win for next-gen heart implants

February 4, 2013 by MassDevice staff

Medical device company Medtronic wins CE Mark approval in the European Union for its next-generation family of Evera implantable cardioverter-defibrillators.

Medtronic logo

Medtronic (NYSE:MDT) touted CE Mark approval in the European Union for its next-generation Evera portfolio of implantable cardioverter-defibrillators.

European regulators approved the new family of ICDs, which boasts a battery life of up to 11 years and features a thinner, more contoured designed that may fit better inside the body, the company announced today.

Sign up to get our free newsletters delivered right to your inbox.

The Evera implants, which are not yet approved for the U.S., also feature "SmartShock 2.0," the new iteration of Medtronic's shock reduction algorithms that helps the device better distinguish between dangerous and harmless heart rhythms, according to a press release.

"Our new, Evera family of ICDs delivers on our strategy to develop a comprehensive system to reduce many common complications that have been part of receiving an ICD," Medtronic tachycardia business general manager and vice president Dr. Marshall Stanton said in prepared remarks. "We have introduced a unique shape to enhance patient comfort, incorporated the most advanced shock reduction technology available, developed a longer-lasting battery than its predecessors, while using the most reliable ICD lead (Sprint Quattro) available."